In a Phase 2/3 clinical trial, AB Science demonstrated that Mastinib in combination with Rilutek (riluzole) slowed functional decline of patients with ALS who have typical disease progression by 27% after 11 months of treatment. AB Science is now setting up a Phase 3 trial to confirm the results and gather more data in support of a new marketing application to the European Medicine Agency (EMA). Click here to view the full article.
